Healthcare co-chair and FDA Partner Bryant Godfrey spoke with Bloomberg Law regarding the FDA's scrutiny by federal lawmakers and regulatory attorneys seeking clarity on the agency's authority over social media influencers promoting prescription drugs without clear warnings on the risks. The agency "should issue formal guidance" to "provide a little bit more clarity about who's responsible for what in this case and what FDA touches and what they don't touch," said Bryant Godfrey.
PRESS RELEASE
23 February 2024
Bryant Godfrey Speaks To Bloomberg Law About TikToker Drug Ads
Foley Hoag LLP
Contributor
Foley Hoag provides innovative, strategic legal services to public, private and government clients. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse experiences of our lawyers contribute to the exceptional senior-level service we deliver to clients.
Healthcare co-chair and FDA Partner Bryant Godfrey spoke with Bloomberg Law regarding the FDA’s scrutiny by federal lawmakers and regulatory attorneys seeking clarity...